Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.87
13.78
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zhejiang Xianju Pharmaceutical Co Ltd
Long-Term Debt
Zhejiang Xianju Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zhejiang Xianju Pharmaceutical Co Ltd
SZSE:002332
|
Long-Term Debt
¥44m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-10%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Debt
¥104.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Long-Term Debt
¥158.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Debt
¥58.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Debt
¥195.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
118%
|
CAGR 10-Years
42%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Debt
¥192.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhejiang Xianju Pharmaceutical Co Ltd
Glance View
In the heart of eastern China, Zhejiang Xianju Pharmaceutical Co., Ltd. stands as a testament to China's evolving pharmaceutical prowess. Founded in 1972, Xianju Pharmaceutical has carved out a niche in the global healthcare market by specializing in the production of corticosteroids and hormone APIs (Active Pharmaceutical Ingredients). What sets Xianju apart is its relentless focus on research and development, enabling the company to produce a wide array of steroid and hormone products that cater to both domestic and international markets. The innovation pipeline is fueled by a robust R&D team that ensures the company remains at the forefront of pharmaceutical advancements, allowing it to consistently meet the stringent quality standards expected in this highly regulated industry. The company's financial engine runs on its ability to manufacture these high-demand products efficiently and at scale, leveraging advanced technologies and integrated production processes. This operational efficiency provides Xianju a competitive edge in price stability and market reach. The revenue stream is diversified yet strategically concentrated on its core competencies, allowing Xianju to capitalize on rising global demands for hormone therapies and steroid-related medical treatments. By maintaining strong relationships with global partners and continuously expanding its distribution networks, Zhejiang Xianju Pharmaceutical not only sustains its profitability but also plays a critical role in shaping healthcare outcomes around the world. The company's growth trajectory suggests a finely balanced strategy that combines innovation, production excellence, and market expansion.
See Also
What is Zhejiang Xianju Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
44m
CNY
Based on the financial report for Sep 30, 2024, Zhejiang Xianju Pharmaceutical Co Ltd's Long-Term Debt amounts to 44m CNY.
What is Zhejiang Xianju Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
-10%
Over the last year, the Long-Term Debt growth was -62%. The average annual Long-Term Debt growth rates for Zhejiang Xianju Pharmaceutical Co Ltd have been -51% over the past three years , -48% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
